What is R&G PharmaStudies Co., Ltd.'s (301333.SZ) StockRank?

MoatMap's StockRank for R&G PharmaStudies Co., Ltd. (301333.SZ) is 38/100, with a Hold signal. This is a composite score combining Quality (64), Value (26), and Momentum (39) factor ranks across MoatMap's 19,000+ stock universe.

Does R&G PharmaStudies Co., Ltd. have an economic moat?

R&G PharmaStudies Co., Ltd. (301333.SZ) has a Quality factor score of 64/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is R&G PharmaStudies Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for R&G PharmaStudies Co., Ltd. (301333.SZ) is Hold, based on a StockRank of 38/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is R&G PharmaStudies Co., Ltd. in?

R&G PharmaStudies Co., Ltd. (301333.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

301333.SZ

HOLDREMOVE

R&G PharmaStudies Co., Ltd. · Healthcare · China · $724M · Avg Vol: $10M/d

StockRank

P/E (TTM)

32.7x

ROE

7.0%

D/E

0.0x

Dividend %

0.3%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

While R&G PharmaStudies operates in the clinical research space, domestic Chinese biotech funding has dried up, and geopolitical headwinds (such as the US Biosecure Act) create severe structural risks for Chinese contract research organizations.

COMPANY DESCRIPTION

R&G PharmaStudies Co., Ltd. is a leading Chinese Contract Research Organization (CRO) providing comprehensive clinical trial services for pharmaceutical and biotechnology companies. The company offers end-to-end solutions from Phase I to IV clinical trials, supported by a vast network of clinical trial sites and deep regulatory expertise in China. It is a critical partner for domestic and multinational drug developers seeking accelerated market approvals.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	94M	107M	110M	126M	10.1%
EPS	0.20	0.31	0.22	0.21	1.2%
Shares	96M	96M	97M	97M	+0.6%
Debt	2M	1M	15M	7M	41.6%
Equity	235M	258M	271M	291M	7.4%
Op CF	19M	28M	23M	17M	-4.3%
Inv CF	-2M	-104M	-7M	3M	—
Fin CF	153M	-3M	-7M	-10M	—

PRICE (1M)-27.8%

SMA 50SMA 200

$6.81

RSI (14)

31.3

52W High

$13.56

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

7.8%66.7

ROE

7.0%62.6

GP/Assets

12.5%30.7

Op. Margin

12.0%69.8

FCF/Assets

2.3%58.8

Piotroski

—55.8

Int. Cover

50.0x91.4

D/E Ratio

0.00x94.4

Current Ratio

6.01x76.0

Value

P/E (TTM)

32.7x34.0

EV/EBITDA

21.1x17.2

P/FCF

606.5x13.5

P/B

2.2x52.0

P/S

4.9x41.9

Div Yield

0.3%9.3

Momentum

52W High %

50%23.9

RS 6M

-23%49.8

SMA 50/200

0.97x53.3

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+29%40.8

Q Growth

-13%30.1

FUNDAMENTALS

Market Cap

$724M

P/E (Forward)

25.3x

Gross Margin

33.3%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 301333.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
301333.SZ	R&G PharmaStudies Co., Ltd.(you)	$724M	38	HOLD
688767.SS	Hangzhou Biotest Biotech Co.,Ltd.	$842M	39	HOLD
1477.HK	Ocumension Therapeutics	$636M	37	HOLD
688399.SS	Jiangsu Bioperfectus Technologies Co., Ltd.	$658M	34	SELL
301080.SZ	Acrobiosystems Co.,Ltd.	$1.0B	38	HOLD
603590.SS	Beijing Konruns Pharmaceutical Co.,Ltd.	$810M	33	SELL
688293.SS	Shanghai OPM Biosciences Co., Ltd.	$898M	42	HOLD
688658.SS	Youcare Pharmaceutical Group Co., Ltd.	$1.2B	39	HOLD
003020.SZ	Hefei Lifeon Pharmaceutical Co., Ltd.	$557M	45	HOLD
002880.SZ	Shenzhen Weiguang Biological Products Co., Ltd.	$845M	48	HOLD

Peer medians: ROE 4.7% · P/E 27.6x · Gross margin 53.1%

R&G PharmaStudies Co., Ltd. (301333.SZ) — Stock Score Summary

R&G PharmaStudies Co., Ltd. (301333.SZ) has a MoatMap StockRank of 38/100 based on Quality (64/100), Value (26/100), and Momentum (39/100) factor scores. The current signal is HOLD. While R&G PharmaStudies operates in the clinical research space, domestic Chinese biotech funding has dried up, and geopolitical headwinds (such as the US Biosecure Act) create severe structural risks for Chinese contract research organizations.

Key Financial Metrics

Price	$6.81
Market Cap	$724M
P/E (TTM)	32.69
P/E (Forward)	25.29
Price/Book	2.20
Return on Equity	7.0%
Return on Invested Capital	7.8%
Debt/Equity	0.35
Gross Margin	33.3%
Operating Margin	12.0%
Revenue Growth	26.2%
Dividend Yield	0.3%
Free Cash Flow	$1M

R&G PharmaStudies Co., Ltd. operates in the Biotechnology industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is R&G PharmaStudies Co., Ltd.’s (301333.SZ) StockRank?: MoatMap’s StockRank for R&G PharmaStudies Co., Ltd. (301333.SZ) is 38/100, with a Hold signal. It is a composite of Quality (64), Value (26), and Momentum (39) factor ranks across MoatMap’s 19,000+ stock universe.
Does R&G PharmaStudies Co., Ltd. have an economic moat?: R&G PharmaStudies Co., Ltd. (301333.SZ) has a Quality factor score of 64/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is R&G PharmaStudies Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for R&G PharmaStudies Co., Ltd. (301333.SZ) is Hold, based on a StockRank of 38/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is R&G PharmaStudies Co., Ltd. in?: R&G PharmaStudies Co., Ltd. (301333.SZ) operates in the Healthcare sector, specifically the Biotechnology industry (China).